Establishment and Validation of Prognostic Nomograms for Patients with Metastatic Pulmonary Large Cell Neuroendocrine Carcinoma

Overview

Journal Cancer Control

Specialty Oncology

Date 2024 Aug 12

PMID 39134429

Authors

Xiaoyun Chen

Xingyue Lai

Yedong Huang

Chaosheng Deng

Affiliations

Soon will be listed here.

Abstract

Purpose: Metastatic pulmonary large cell neuroendocrine carcinoma (LCNEC) is an aggressive cancer with generally poor outcomes. Effective methods for predicting survival in patients with metastatic LCNEC are needed. This study aimed to identify independent survival predictors and develop nomograms for predicting survival in patients with metastatic LCNEC.

Patients And Methods: We conducted a retrospective analysis using the Surveillance, Epidemiology, and End Results (SEER) database, identifying patients with metastatic LCNEC diagnosed between 2010 and 2017. To find independent predictors of cancer-specific survival (CSS), we performed Cox regression analysis. A nomogram was developed to predict the 6-, 12-, and 18-month CSS rates of patients with metastatic LCNEC. The concordance index (C-index), area under the receiver operating characteristic (ROC) curves (AUC), and calibration curves were adopted with the aim of assessing whether the model can be discriminative and reliable. Decision curve analyses (DCAs) were used to assess the model's utility and benefits from a clinical perspective.

Results: This study enrolled a total of 616 patients, of whom 432 were allocated to the training cohort and 184 to the validation cohort. Age, T staging, N staging, metastatic sites, radiotherapy, and chemotherapy were identified as independent prognostic factors for patients with metastatic LCNEC based on multivariable Cox regression analysis results. The nomogram showed strong performance with C-index values of 0.733 and 0.728 for the training and validation cohorts, respectively. ROC curves indicated good predictive performance of the model, with AUC values of 0.796, 0.735, and 0.736 for predicting the 6-, 12-, and 18-month CSS rates of patients with metastatic LCNEC in the training cohort, and 0.795, 0.801, and 0.780 in the validation cohort, respectively. Calibration curves and DCAs confirmed the nomogram's reliability and clinical utility.

Conclusion: The new nomogram was developed for predicting CSS in patients with metastatic LCNEC, providing personalized risk evaluation and aiding clinical decision-making.

References

Shan Q, Fan Y, Guo J, Han X, Wang H, Wang Z . Relationship between tumor size and metastatic site in patients with stage IV non-small cell lung cancer: A large SEER-based study. PeerJ. 2019; 7:e7822. PMC: 6790223. DOI: 10.7717/peerj.7822. View

Park S, Park J, Kim H, Park S . Review of Statistical Methods for Evaluating the Performance of Survival or Other Time-to-Event Prediction Models (from Conventional to Deep Learning Approaches). Korean J Radiol. 2021; 22(10):1697-1707. PMC: 8484151. DOI: 10.3348/kjr.2021.0223. View

Miyoshi T, Umemura S, Matsumura Y, Mimaki S, Tada S, Makinoshima H . Genomic Profiling of Large-Cell Neuroendocrine Carcinoma of the Lung. Clin Cancer Res. 2016; 23(3):757-765. DOI: 10.1158/1078-0432.CCR-16-0355. View

Jiang T, Sun H, Li N, Jiang T . Metastasis pattern and prognosis of large cell neuroendocrine carcinoma: a population-based study. J Cancer Res Clin Oncol. 2023; 149(15):13511-13521. PMC: 10590330. DOI: 10.1007/s00432-023-04975-w. View

Kinslow C, May M, Saqi A, Shu C, Chaudhary K, Wang T . Large-Cell Neuroendocrine Carcinoma of the Lung: A Population-Based Study. Clin Lung Cancer. 2019; 21(2):e99-e113. DOI: 10.1016/j.cllc.2019.07.011. View

Gu J, Gong D, Wang Y, Chi B, Zhang J, Hu S . The demographic and treatment options for patients with large cell neuroendocrine carcinoma of the lung. Cancer Med. 2019; 8(6):2979-2993. PMC: 6558599. DOI: 10.1002/cam4.2188. View

Cao L, Zhao L, Wang M, Zhang X, Yang Z, Liu Y . Clinicopathological characteristics and prognosis of pulmonary large cell neuroendocrine carcinoma aged ≥65 years. PeerJ. 2019; 7:e6824. PMC: 6532618. DOI: 10.7717/peerj.6824. View

Xi J, Zhao M, Zheng Y, Liang J, Hu Z, Huang Y . Development and validation of a nomogram for predicting the overall survival of patients with lung large cell neuroendocrine carcinoma. Transl Cancer Res. 2022; 9(8):4943-4957. PMC: 8799202. DOI: 10.21037/tcr-20-780. View

Derks J, Hendriks L, Buikhuisen W, Groen H, Thunnissen E, van Suylen R . Clinical features of large cell neuroendocrine carcinoma: a population-based overview. Eur Respir J. 2015; 47(2):615-24. DOI: 10.1183/13993003.00618-2015. View

10.

Fitzgerald M, Saville B, Lewis R . Decision curve analysis. JAMA. 2015; 313(4):409-10. DOI: 10.1001/jama.2015.37. View

11.

Ferrara M, Stefani A, Simbolo M, Pilotto S, Martini M, Lococo F . Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities. Front Oncol. 2021; 11:650293. PMC: 8081906. DOI: 10.3389/fonc.2021.650293. View

12.

Balachandran V, Gonen M, Smith J, DeMatteo R . Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015; 16(4):e173-80. PMC: 4465353. DOI: 10.1016/S1470-2045(14)71116-7. View

13.

Song Z, Zou L . Risk factors, survival analysis, and nomograms for distant metastasis in patients with primary pulmonary large cell neuroendocrine carcinoma: A population-based study. Front Endocrinol (Lausanne). 2022; 13:973091. PMC: 9623680. DOI: 10.3389/fendo.2022.973091. View

14.

Sherman S, Rotem O, Shochat T, Zer A, Moore A, Dudnik E . Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC). Lung Cancer. 2020; 143:40-46. DOI: 10.1016/j.lungcan.2020.03.008. View

15.

Lo Russo G, Pusceddu S, Proto C, Macerelli M, Signorelli D, Vitali M . Treatment of lung large cell neuroendocrine carcinoma. Tumour Biol. 2016; 37(6):7047-57. DOI: 10.1007/s13277-016-5003-4. View

16.

Baine M, Rekhtman N . Multiple faces of pulmonary large cell neuroendocrine carcinoma: update with a focus on practical approach to diagnosis. Transl Lung Cancer Res. 2020; 9(3):860-878. PMC: 7354156. DOI: 10.21037/tlcr.2020.02.13. View

17.

Chen K, Dai P, Ni J, Xiang Y, Gu L . The prognosis analysis of organ metastatic patterns in lung large cell neuroendocrine carcinoma: A population-based study. Front Oncol. 2022; 12:1050800. PMC: 9773085. DOI: 10.3389/fonc.2022.1050800. View

18.

Komiya T, Ravindra N, Powell E . Role of Immunotherapy in Stage IV Large Cell Neuroendocrine Carcinoma of the Lung. Asian Pac J Cancer Prev. 2021; 22(2):365-370. PMC: 8190341. DOI: 10.31557/APJCP.2021.22.2.365. View

19.

Collins G, Reitsma J, Altman D, Moons K . Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ. 2015; 350:g7594. DOI: 10.1136/bmj.g7594. View

20.

Eichhorn F, Harms A, Warth A, Muley T, Winter H, Eichhorn M . PD-L1 expression in large cell neuroendocrine carcinoma of the lung. Lung Cancer. 2018; 118:76-82. DOI: 10.1016/j.lungcan.2018.02.003. View